文献速递胸部肿瘤放疗

局部晚期非小细胞肺癌中「中间位置策略」与「内靶区策略」的比较:随机非比较II期研究Mid-P的临床结果

"Mid-P strategy" versus "internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P.
PubMed 文献 · Radiother Oncol · 2024-07-14

这项前瞻性随机非比较单中心II期研究纳入54例局部晚期非小细胞肺癌患者,按2:1随机接受中间位置(Mid-P)策略或内靶区(ITV)策略的根治性适形放疗。Mid-P组1年无进展生存率为38%(单侧95%CI 25%至未达到),ITV组为47%(95%CI 27%至未达到)。作者结论认为Mid-P策略局部控制和生存仍较差,且该策略未整合入常规软件、被认为耗时,不能在临床试验外推荐用于根治性常规分割适形放疗的局部晚期非小细胞肺癌。

要点

  • Mid-P组1年无进展生存率38%(单侧95%CI 25%至未达到),ITV组47%(95%CI 27%至未达到)。
  • 无论采用哪种策略,局部区域失败作为首次事件主要发生在放疗野内。
  • 两种策略均观察到急性和中期放射性毒性。

核心结论

  • 作者结论认为,在这项比较Mid-P策略与ITV策略的前瞻性随机非比较单中心研究中,采用Mid-P策略的局部控制和生存仍较差。
  • 作者指出,由于Mid-P策略未整合入常规软件且被认为耗时,该策略不能在临床试验外推荐用于根治性常规分割适形放疗的局部晚期非小细胞肺癌。

研究设计与样本

  • 前瞻性非比较随机单中心II期试验,纳入未手术、无转移、既往未放疗且病理证实的局部晚期非小细胞肺癌成人患者,接受根治性常规分割适形放疗(联合或不联合化疗)。
  • 患者按2:1随机分配至Mid-P策略组或ITV策略组。
  • 采用Fleming单阶段设计(单侧α=0.1,80%把握度,P0=30%,P1=50%),计划在Mid-P组入组36例患者;ITV组用于确保无选择偏倚。
  • 主要终点为1年无进展生存率。
  • 2012年9月至2018年5月共纳入54例合格患者,其中51例进行分析(Mid-P组34例,ITV组17例)。

主要发现

  • Mid-P策略组1年无进展生存率为38%(单侧95%CI 25%至未达到),ITV策略组为47%(95%CI 27%至未达到)。
  • 无论采用哪种策略,局部区域失败作为首次事件主要发生在放疗野内。
  • 两种策略均观察到急性和中期放射性毒性。

临床怎么用

  • 作者结论认为,Mid-P策略不能在临床试验外推荐用于接受根治性常规分割适形放疗的局部晚期非小细胞肺癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Locally advanced non-small cell lung cancer (LA-NSCLC) reported poor 5-year survival rates with frequent local or regional recurrences. Personalized RT may contribute to improve control and clinical outcome. We investigated efficacy and tolerance of "Mid-position" (Mid-P) strategy versus the conventional Internal Target Volume (ITV) strategy in LA-NSCLC patients treated by definitive conformal radiotherapy. METHODS: This prospective non-comparative randomized monocentric phase II trial included adult patients with non-resected, non-metastatic, non-previously irradiated proven LA-NSCLC treated with definitive normo-fractionated conformal radiotherapy (+/- chemotherapy). Allocated patients (randomisation 2:1) were treated using Mid-P or ITV strategy. A Fleming single-stage design (1-sided α = 0.1, 80 % power, P0 = 30 %, P1 = 50 %) planned enrolment of 36 patients in the Mid-P group. The ITV group ensured the absence of selection bias. The primary outcome was 1-year progression-free- survival (1y-PFS) rate. RESULTS: Among 54 eligible patients included from September 2012 to May 2018, 51 patients were analyzed (Mid-P: N = 34; ITV: 17). The 1y-PFS was 38 % (1-sided 95 %CI 25 %-not reached) with Mid-P strategy, and 47 % (95 %CI [27 %-not reached[) with ITV. Loco-regional failure as first event mainly occurred within radiation-field regardless the strategy. Acute and middle-term radiation toxicities were observed with both strategies. CONCLUSION: Local control and survival remain poor using the Mid-P strategy in this prospective randomized non-comparative monocentric study investigating Mid-P strategy versus ITV strategy in LA-NSCLC. Since the Mid-P strategy is not integrated into routine software, and perceived as a time-consuming method, Mid-P strategy cannot be recommended in LA-NSCLCC treated by definitive normo-fractionated conformal radiotherapy outside clinical trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Claude L, Schiffler C, Isnardi V, et al. "Mid-P strategy" versus "internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P. Radiother Oncol. 2024. PMID: 39004227. doi:10.1016/j.radonc.2024.110435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。